Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

Journal of Clinical Oncology

Volumn 25, Issue 15, 2007, Pages 2086-2092

  Eckardt, John R ^a   Von Pawel, Joachim ^a   Pujol, Jean Louis ^a   Papai, Zsolt ^a   Quoix, Elisabeth ^a   Ardizzoni, Andrea ^a   Poulin, Ruth ^a   Preston, Alaknanda J ^a   Dane, Graham ^a   Ross, Graham ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; THROMBOCYTOPENIA; TREATMENT RESPONSE; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SALVAGE THERAPY; SMALL CELL CARCINOMA; SURVIVAL RATE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SALVAGE THERAPY; SURVIVAL RATE; TOPOTECAN;

EID: 34249941781     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.3998     Document Type: Article

References (24)

1. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the Untied States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006
2. Okuno SH, Jett JR: Small cell lung cancer: Current therapy and promising new regimens. Oncologist 7:234-238, 2002
3. Ardizzoni A, Hansen H, Dombernowski P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer SCLC: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096, 1997
4. Depierre A, von Pawel J, Hans K et al: Evaluation of topotecan (Hycamtin) in relapsed small-cell lung cancer (SCLC): A multicentre phase II study. Lung Cancer 18:35, 1997 (abstr 126)
5. Eckardt J, Gralla R, Palmer MC, et al: Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): A phase II study. Ann Oncol 7:107, 1996 (abstr 523)
6. Eckardt J, Depierre A, Ardizzoni A, et al: Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer. Proc Am Soc Clin Oncol 16:452a, 1997 (abstr 1624)
7. von Pawel J, Gatzmeier U, Pujol J-L, et al: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19:1743-1749, 2001
8. Gerrits CJH, Schellens JHM, Burris H, et al: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 5:69-75, 1999
9. Schellens J, Creemers GJ, Beijnen JH, et al: Bioavailability and pharmacokinetics of oral topotecan: A new topoisomerase I inhibitor. Br J Cancer 73:1268-1271, 1996
10. Kruijtzer C, Beijnen J, Rosing H, et al: Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943-2950, 2002
11. Léger F, Loos WJ, Fourcade J, et al: Factors affecting pharmacokinetic variability of oral topotecan: A population analysis. Br J Cancer 90:343-347, 2004
12. GlaxoSmithKline: Hycamtin: Package insert. Philadelphia, PA, GlaxoSmithKline, 2004
13. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979
14. Gwyther SJ, Ross G, Crofts T, et al: Correlation between response, treatment duration and median survival: Single agent intravenous (IV) topotecan in a population of 631 relapsed small cell lung cancer (SCLC) patients. Lung Cancer 41:S235, 2003 (suppl 2, abstr)
15. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
16. Cella D, Eton DT, Fairclough DL, et al: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55:285-295, 2002
17. Cella DF: The Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument, in Gralla RJ, Moinpour CM (eds): Assessing Quality of Life in Patients with Lung Cancer: A Guide for Clinicians. New York, NY, NCM Publishers Inc, 1995
18. Stewart DJ, Dahrouge S, Soltys KM, et al: A phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer. Am J Clin Oncol 18:130-132, 1995
19. Falk SJ, Maughan TS, Laurence VM, et al: Phase II study of carboplatin and Adriamycin as second line chemotherapy in small cell lung cancer. Clin Oncol (R Coll Radiol) 5:85-88, 1993
20. O'Brien MER, Ciuleanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441-5447, 2006
21. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 17:658-667, 1999
22. Gore M, Oza A, Rustin G, et al: A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 38:57-63, 2002
23. Borner M, Scheithauer W, Twelves C, et al: Answering patient's needs: Oral alternative to intravenous therapy. Oncologist 6:12-16, 2001 (suppl 4)
24. Liu G, Franssen E, Fitch MI, et al: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110-115, 1997